Edition:
India

DelMar Pharmaceuticals Inc (DMPI.OQ)

DMPI.OQ on NASDAQ Stock Exchange Capital Market

1.34USD
19 Aug 2020
Change (% chg)

-- (--)
Prev Close
$1.34
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
118,683
52-wk High
$1.53
52-wk Low
$0.38

Select another date:

Wed, Jun 10 2020

BRIEF-DelMar To Acquire Adgero Biopharmaceuticals

* DELMAR TO ACQUIRE ADGERO BIOPHARMACEUTICALS, EXPANDS LATE-STAGE ONCOLOGY PIPELINE

BRIEF-DelMar Pharmaceuticals' VAL-083 Selected To Participate In Global Coalition For Adaptive Research's GBM AGILE Pivotal Study

* GLOBAL COALITION FOR ADAPTIVE RESEARCH (GCAR) SELECTS DELMAR PHARMACEUTICALS' VAL-083 TO PARTICIPATE IN THE GBM AGILE PIVOTAL STUDY, AN ADAPTIVE CLINICAL TRIAL PLATFORM IN GLIOBLASTOMA MULTIFORME Source text for Eikon: Further company coverage:

BRIEF-Delmar Pharmaceuticals To Present Updates Of Two Phase 2 Clinical Trials Of Val-083 At 2020 American Association For Cancer Research Virtual Annual Meeting Ii

* DELMAR PHARMACEUTICALS TO PRESENT UPDATES OF TWO PHASE 2 CLINICAL TRIALS OF VAL-083 AT THE 2020 AMERICAN ASSOCIATION FOR CANCER RESEARCH VIRTUAL ANNUAL MEETING II Source text for Eikon: Further company coverage:

BRIEF-Delmar Pharmaceuticals Reports Q3 Loss Per Share $0.17

* DELMAR PHARMACEUTICALS ANNOUNCES FISCAL THIRD QUARTER 2020 FINANCIAL RESULTS AND RECENT CORPORATE UPDATES

BRIEF-DelMar Pharmaceuticals Provides Enrollment Update In Phase 2 Clinical Trial Of Val-083 For Adjuvant Treatment Of Brain Tumors

* DELMAR PHARMACEUTICALS [NASDAQ:DMPI] PROVIDES ENROLLMENT UPDATE IN PHASE 2 CLINICAL TRIAL OF VAL-083 FOR ADJUVANT TREATMENT OF BRAIN TUMORS

Select another date: